OncoMatch/Clinical Trials/NCT05946213
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Is NCT05946213 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies non-drug interventions for prostate adenocarcinoma.
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage CT3A, CT3B, STAGE III, STAGE IVA (AJCC 8th edition)
Grade: Gleason Score 8-10 (Gleason)
cT3a-T3b by digital exam or imaging (AJCC 8th edition); cT4 by imaging or on digital rectal exam is not allowed; Gleason Score of 8-10
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: androgen deprivation therapy (LHRH agonist, oral anti-androgen) — prostate cancer
Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both luteinizing hormone releasing hormone [LHRH] agonist and oral anti-androgen) is <= 185 days prior to registration
Cannot have received: radiation therapy
Exception: would result in overlap of radiation therapy fields
No prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Cannot have received: radical prostatectomy
No prior radical prostatectomy
Cannot have received: ablative or focal therapy to the prostate (transrectal high-intensity focused ultrasound, transurethral high-intensity focused ultrasound, laser ablation, cryotherapy, irreversible electroporation, vascular-targeted photodynamic therapy)
No prior ablative or focal therapy to the prostate (including, but not limited to, transrectal or transurethral high-intensity focused ultrasound [HIFU], laser ablation, cryotherapy, irreversible electroporation [IRE], and vascular-targeted photodynamic therapy)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham Cancer Center · Birmingham, Alabama
- The Kirklin Clinic at Acton Road · Birmingham, Alabama
- Lewis and Faye Manderson Cancer Center · Tuscaloosa, Alabama
- University of Arkansas for Medical Sciences · Little Rock, Arkansas
- Kaiser Permanente-Deer Valley Medical Center · Antioch, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05946213 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy, radical prostatectomy, ablative or focal therapy to the prostate disqualifies patients from enrollment.
What disease stage is eligible?
Stage CT3A or CT3B or STAGE III or STAGE IVA is required.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages